TLRY · Tilray Brands, Inc.
$4.23
-0.07 (-1.63%)
At close · Jul 20
Market Cap
$493.00M
Shares
116.55M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$821.31M
+4.1%
FY2025
Net Income
-$2.19B
-792.6%
FY2025
Gross Margin
29.29%
+1pp
FY2025
Operating Margin
-277.93%
-255.8pp
FY2025
Diluted EPS
-$24.60
-645.5%
FY2025
Operating Cash Flow
-$94.6M
-206.1%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|---|
| $858.28M | $821.31M | $788.94M | $627.12M | $628.37M | $513.09M | $210.48M | $166.98M | $43.13M | |
| $620.72M | $580.74M | $565.59M | $480.16M | $511.56M | $389.9M | $185.83M | $135.79M | $28.86M | |
| $237.55M | $240.57M | $223.35M | $146.96M | $116.82M | $123.18M | $24.66M | -$23.5M | $14.28M | |
| — | 29.29% | 28.31% | 23.43% | 18.59% | 24.01% | 11.71% | -14.07% | 33.1% | |
| $215K | $284K | $635K | $682K | $1.52M | $830K | $4.41M | $6.56M | $4.26M | |
| — | — | — | — | — | — | $54.67M | $61.08M | $15.37M | |
| $180.42M | $167.32M | $167.36M | $165.16M | $162.8M | $111.58M | $85.88M | $81.97M | $31.31M | |
| — | — | — | — | — | $27.31M | $11M | $9.82M | — | |
| $149.33M | — | — | — | $154.59M | $67.83M | $18.65M | $15.85M | $3.56M | |
| $22.96M | $34.28M | $15.58M | $9.25M | $795K | $0 | — | — | — | |
| $1.73B | $2.52B | $398.1M | $1.52B | $727.22M | $255.35M | $200.06M | $182.44M | — | |
| -$1.49B | -$2.28B | -$174.75M | -$1.37B | -$610.4M | -$132.17M | -$201.12M | -$301.7M | -$57.65M | |
| — | -277.93% | -22.15% | -218.41% | -97.14% | -25.76% | -95.55% | -180.68% | -133.67% | |
| -$412.88M | — | — | — | -$455.81M | -$64.34M | -$182.47M | -$285.85M | -$54.09M | |
| — | $41.33M | $49.26M | $46.61M | $39.68M | $30.9M | $25.64M | — | — | |
| — | $11.38M | $12.83M | $33.03M | $11.74M | $2.93M | $798K | $149K | — | |
| $54.53M | $10.28M | -$37.84M | -$66.91M | $197.67M | -$184.84M | -$10.33M | $2.5M | $1.82M | |
| -$8.11M | — | — | -$7.97M | $5.21M | $9.08M | -$5.98M | -$4.5M | — | |
| -$1.46B | -$2.3B | -$249.02M | -$1.45B | -$440.67M | -$344.99M | -$276.68M | -$329.62M | -$72.17M | |
| -$121.91M | -$121.02M | -$26.62M | -$7.18M | -$6.54M | -$8.97M | -$5.6M | -$8.45M | $34K | |
| -$1.34B | -$2.19B | -$244.98M | -$1.45B | -$476.8M | -$367.42M | -$271.07M | -$321.17M | -$67.72M | |
| — | -266.25% | -31.05% | -231.64% | -75.88% | -71.61% | -128.79% | -192.34% | -157.02% | |
| $9.5M | $5.38M | $22.58M | $9.66M | $42.67M | $31.41M | $1.71M | -$11.06M | — | |
| -$1.34B | -$2.19B | -$241.87M | -$1.48B | -$650.23M | -$214.6M | -$272.59M | -$316.02M | -$67.83M | |
| USD/shares | — | -$24.60 | -$3.30 | -$23.50 | -$9.90 | -$13.60 | -$4.70 | -$1.80 | — |
| USD/shares | — | -$24.60 | -$3.30 | -$23.50 | -$9.90 | -$13.60 | -$4.70 | -$1.80 | — |
| shares | — | 89.03M | 74.26M | 61.8M | 48.12M | 26.95M | 12.6M | 10.05M | 8.3M |
| shares | — | 89.03M | 74.26M | 61.8M | 48.12M | 26.95M | 12.6M | 10.05M | 8.3M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Drug Manufacturers - Specialty & Generic median 2.22×
EV/EBIT
—
Drug Manufacturers - Specialty & Generic median 34.94×
P/E (TTM)
—
Drug Manufacturers - Specialty & Generic median 19.97×
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Distribution Business | $271,228,000 | $258,740,000 | $258,770,000 | $259,747,000 | $277,300,000 | — | $119,427,000 |
| Cannabis Segment | $249,001,000 | $272,798,000 | $220,430,000 | $237,522,000 | $201,392,000 | — | — |
| Beverage Alcohol Business | $240,595,000 | $202,094,000 | $95,093,000 | $71,492,000 | $28,599,000 | — | — |
| Wellness Business | $60,485,000 | $55,310,000 | $52,831,000 | $59,611,000 | $5,794,000 | — | — |
| Beverage Alcohol | — | — | — | $71,492,000 | $28,599,000 | — | — |
| Cannabis Business | — | — | — | — | $201,392,000 | — | $59,876,000 |
| Cannabis | — | — | — | $237,522,000 | $201,392,000 | $129,896,000 | $59,876,000 |
| Distribution | — | — | — | $259,747,000 | $277,300,000 | $275,430,000 | — |
| Tilray Pharma Segment | — | $258,740,000 | $258,770,000 | $259,747,000 | — | — | — |
| Wellness | — | — | — | $59,611,000 | $5,794,000 | — | — |
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| EMEA | $323,350,000 | $296,450,000 | $284,567,000 | $296,911,000 | $279,062,000 | — | $271,291,000 | — |
| United States | $273,695,000 | $233,141,000 | $123,284,000 | $103,991,000 | — | $53,782,000 | — | $23,516,000 |
| Canada | $212,860,000 | $243,722,000 | $201,361,000 | $210,141,000 | — | $120,581,000 | — | $130,291,000 |
| Rest of World | $11,404,000 | $15,629,000 | $17,912,000 | $17,329,000 | $4,903,000 | — | $4,372,000 | — |
| North America | — | — | — | — | $229,120,000 | — | $129,663,000 | — |
| Others Countries | — | — | — | — | — | $36,119,000 | — | $13,172,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Adultuse Cannabis Products | $224,048,000 | $266,846,000 | $214,319,000 | — | — | — | — | — |
| International Cannabis Products | $63,356,000 | $53,295,000 | $43,559,000 | — | — | — | — | — |
| Medical Cannabis Products | $24,998,000 | $25,211,000 | $25,000,000 | — | — | — | — | — |
| Wholesale Cannabis Products | $18,207,000 | $25,340,000 | $1,436,000 | — | — | — | — | — |
| Accessories and Other | — | — | — | — | — | $838,000 | — | $255,000 |
| Beverage Alcohol Excise Taxes | — | — | — | -$3,467,000 | -$1,062,000 | — | — | — |
| Beverage Alcohol Revenue | — | — | — | $74,959,000 | $29,661,000 | — | — | — |
| Beverage Alcohol Revenue Net | — | — | — | $71,492,000 | $28,599,000 | — | — | — |
| Cannabis Excise Taxes | — | — | — | -$63,369,000 | -$62,942,000 | — | -$23,581,000 | — |
| Cannabis Extracts | — | — | — | — | — | $39,986,000 | — | $24,139,000 |
| Cannabis | — | — | — | — | — | $133,605,000 | — | $107,147,000 |
| Cannabis Revenue | — | — | — | $300,891,000 | $264,334,000 | — | $153,477,000 | — |
| Cannabis Revenue Net | — | — | — | $237,522,000 | $201,392,000 | — | $129,896,000 | — |
| Distribution Revenue | — | — | — | $259,747,000 | $277,300,000 | — | $275,430,000 | — |
| Dried Cannabis | — | — | — | — | — | $92,781,000 | — | $82,753,000 |
| Hemp | — | — | — | — | — | $76,877,000 | — | $59,832,000 |
| Hemp Products | — | — | — | — | — | $76,877,000 | — | $59,832,000 |
| Wellness Revenue | — | — | — | $59,611,000 | $5,794,000 | — | — | — |
Key facts
CIK
1731348
CUSIP
88688T209
13F (30d)
27 filings
26 filers
Visit website
Investor relations